Penn Study Illuminates Why Cancers Caused by BRCA Mutations Recur

November 10, 2022 11:36 am

Findings uncover possible drivers of recurrent breast and ovarian cancers among women carrying high-risk genetic mutations, pointing to methods to more effectively treat disease

PHILADELPHIA — Researchers at the University of Pennsylvania’s Basser Center for BRCA at the Abramson Cancer … Read more

Black women less likely to receive guideline-concordant therapy for ovarian cancer

November 9, 2022 11:23 am

by Matthew Shinkle

Black women in the U.S. appeared less likely than white women to receive guideline-concordant treatment for ovarian cancer, according to a study published in Journal of the National Comprehensive Cancer Network.

Even among white women, the … Read more

Restoring the gut biome after antibiotics could lead to better outcomes for ovarian cancer patients

November 8, 2022 11:09 am

by Cleveland Clinic

Reassessing antibiotic dosage and type could improve survival rates in deadliest gynecologic malignancy, Cleveland Clinic research finds

Newswise — CLEVELAND – Antibiotics routinely used in ovarian cancer care indiscriminately kill gut bacteria, leading to faster cancer progression … Read more

Ovarian cancer surveillance results in earlier diagnosis for women with faulty BRCA genes who want to defer surgery

November 1, 2022 4:17 pm

by British Medical Journal

Regularly monitoring women with faulty BRCA genes that make them highly susceptible to ovarian cancer results in earlier stage diagnosis in those who want to defer preventive surgery, finds research published online in the Journal of Read more

Eligibility Not Responsible for Under Representations in Cancer Clinical Trials

October 18, 2022 10:16 am

by Jessica Nye, PhD

Left image: Eligibility and opportunity for participation in cancer clinical trials was found to be similar across race, level of disadvantage, and residential area. Source: Getty Images

Eligibility was not found to drive disparities in clinical … Read more

Study could help recommend the best treatment for women with early-stage mucinous ovarian cancer

October 12, 2022 1:23 pm

by Emily Henderson, B.Sc.

A global study into mucinous ovarian cancer could help oncologists recommend the best treatment for women who are diagnosed early with the condition.

By looking down a microscope for two different ‘patterns of invasion’ – the … Read more

Identifying the Underlying Causes of Ovarian Cancer

October 6, 2022 1:48 pm

by Cedars-Sinai

New Studies Led by Cedars-Sinai Investigators Help Pinpoint Genetic Risk Factors Tied to Increased Risk of Ovarian Cancer and Suggest How to Better Identify Women Most At Risk

Image on left: Simon Gayther, PhD, professor of Biomedical Sciences, Read more

Pembrolizumab Plus Bevacizumab and Cyclophosphamide Shows Promising Efficacy, Tolerability in Recurrent Ovarian Cancer

September 26, 2022 9:49 am

by Megan Hollasch

Real-world data from a retrospective study showed that pembrolizumab combined with the anti-VEGF agent bevacizumab plus oral metronomic cyclophosphamide displayed minimal toxicity in a significant number of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal Read more

Ovarian Cancer Detection Takes a Step Forward

September 12, 2022 1:45 pm

A new type of technology can capture stray ovarian cancer cells from a simple blood test and successfully predict cancer in people who have a lesion or cyst in the pelvic region, according to a new study by a Wilmot … Read more

Fertility Concerns a Significant Issue for Gynecologic Cancer Survivors

July 29, 2022 12:59 pm

by Jessica Nye, PhD

A systematic review found that fertility and parenthood were important and affected quality of life for young patients with gynecologic cancers; however, counseling and referral to fertility services is suboptimal. These findings were published in The Read more

Understanding the genetic testing-related information needs of ovarian cancer patients

July 29, 2022 11:45 am

Reviewed by Emily Henderson, B.Sc.

JMIR Publications recently published “Understanding the Information Needs of Patients With Ovarian Cancer Regarding Genetic Testing to Inform Intervention Design: Interview Study” in JMIR Cancer, which reported that experts in gynecological cancer care recommend that … Read more

Meta-Analysis Examines Link Between Aspirin Use and Ovarian Cancer Risk

July 28, 2022 10:32 am

by The ASCO Post Staff

Frequent aspirin use may be linked with lower ovarian cancer risk in individuals with multiple risk factors, according to a new study published by Hurwitz et al in the Journal of Clinical Oncology.

“Ovarian … Read more

Effects of Food Insecurity Interventions on Cancer Treatment Adherence, Completion

July 13, 2022 11:22 am

by Vicki Moore, PhD

A recent study evaluated the effects programs aimed at addressing food insecurity have on treatment outcomes for patients with cancer. Each intervention seemed beneficial, with a voucher-plus-pantry program appearing to be the most effective. The study’s … Read more

Breast, Ovarian Cancer Study Finds Ties Between Types of BRCA Alterations, Treatment Response

July 7, 2022 10:30 am

NEW YORK – Epigenetic changes to the promoter regions of BRCA1 appear to have a different effect on treatment response than genomic alterations in BRCA1 or BRCA2 in triple-negative breast cancer (TNBC) or ovarian carcinoma patients, new research suggests.

For Read more

Examining factors that may impact ovarian cancer survival disparities

June 20, 2022 10:33 am

by Coco Davis/ Fred Hutchinson Cancer Research Center

Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy among women in the United States (US). Although the incidence rate is higher among White women, Black women have the lower survival … Read more

Real-World Data Identify Significant Differences in Tolerability Among Approved PARP Inhibitors in Ovarian Cancer

June 14, 2022 11:57 am

by Lindsey Fischer

A real-world analysis showed that the proportion of women with ovarian cancer who required dose modifications or treatment discontinuations while receiving PARP inhibitors differed significantly between olaparib, niraparib, and rucaparib.

Patients with ovarian cancer treated with FDA-approved

Read more

Break Through Cancer Announces $50 Million in Grants to Researchers From Five Top Cancer Research Centers

April 19, 2022 9:13 am

by the ASCO Post Staff

Today, 1 year after its founding, Break Through Cancer announced $50 million in grants to support several cutting-edge research projects using a novel “TeamLab” structure—designed to maximize interdisciplinary collaboration among researchers at Dana-Farber Cancer Institute, … Read more

New Clue to Risk of Peritoneal Cancer After Prophylactic Salpingo-Oophorectomy

April 5, 2022 3:27 pm

by Charles Bankhead

— Women with BRCA variant and serous tubal intraepithelial carcinoma had a 34-fold greater risk

The presence of serous tubal intraepithelial carcinoma (STIC) at the time of risk-reducing salpingo-oophorectomy (RRSO) significantly increased the risk of peritoneal carcinomatosis … Read more

MAPK mutations linked to longer survival in ovarian cancer subset

March 24, 2022 10:43 am

by Jennifer Southall

 

Women with mitogen-activated protein kinase-mutated low-grade serous ovarian/peritoneal carcinoma experienced significantly longer PFS and OS compared with women without these mutations, according to study results.

The findings, presented during the Society of Gynecologic Oncology 2022 Annual … Read more

Researchers Use US to Predict Ovarian Cancer

March 22, 2022 11:13 am

Approach can help radiologists in a busy clinical practice assess lesions more quickly

The appearance of ovarian lesions on ultrasound is an effective predictor of cancer risk that can help women avoid unnecessary surgery, according to a new study published … Read more